ESSA Pharma Inc (EPIX) - Total Liabilities
Based on the latest financial reports, ESSA Pharma Inc (EPIX) has total liabilities worth $1.60 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ESSA Pharma Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how ESSA Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See ESSA Pharma Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
ESSA Pharma Inc Competitors by Total Liabilities
The table below lists competitors of ESSA Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Metalsgrove Mining Ltd
AU:MGA
|
Australia | AU$123.69K |
|
Oncosil Medical Ltd
AU:OSL
|
Australia | AU$3.29 Million |
|
RS Public Company Limited
BK:RS
|
Thailand | ฿5.35 Billion |
|
Cinevista Limited
NSE:CINEVISTA
|
India | Rs818.69 Million |
|
Viking Mines Ltd
AU:VKA
|
Australia | AU$370.98K |
|
Pets at Home Group Plc
LSE:PETS
|
UK | GBX681.60 Million |
|
Mainz Biomed BV
NASDAQ:MYNZ
|
USA | $4.69 Million |
|
Pryme BV
OL:PRYME
|
Norway | Nkr20.61 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down ESSA Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ESSA Pharma Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 69.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ESSA Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ESSA Pharma Inc (2012–2024)
The table below shows the annual total liabilities of ESSA Pharma Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | $3.51 Million | +0.32% |
| 2023-09-30 | $3.50 Million | +46.42% |
| 2022-09-30 | $2.39 Million | -42.62% |
| 2021-09-30 | $4.16 Million | +212.57% |
| 2020-09-30 | $1.33 Million | -76.20% |
| 2019-09-30 | $5.59 Million | -18.53% |
| 2018-09-30 | $6.87 Million | -30.52% |
| 2017-09-30 | $9.88 Million | -9.67% |
| 2016-09-30 | $10.94 Million | +256.80% |
| 2015-09-30 | $3.07 Million | +37.63% |
| 2014-09-30 | $2.23 Million | +1142.16% |
| 2013-09-30 | $179.34K | +134702.32% |
| 2012-09-30 | $133.04 | -- |
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.